Product Description
The pharmacological profile of DSP-6952, a novel 5-HT4 receptor partial agonist, was investigated to evaluate the potential use for GI disorders, and to compare its effects in some GI dysfunction models with those of clinically efficacious prokinetic agents. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/29428470/)
Mechanisms of Action: 5-HT4 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Dainippon Sumitomo Pharma America
Company Location:
Company Founding Year: 2000
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Irritable Bowel Syndrome|Constipation
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
JapicCTI-173785 |
JapicCTI-173785 | P1 |
Completed |
Healthy Volunteers |
2018-03-31 |
|||
JapicCTI-205093 |
JapicCTI-205093 | P1 |
Completed |
Healthy Volunteers |
2017-12-17 |
|||
JapicCTI-173784 |
JapicCTI-173784 | P1 |
Completed |
Healthy Volunteers |
2012-07-31 |
|||
JapicCTI-163459 |
JapicCTI-163459 | P2 |
Completed |
Constipation|Irritable Bowel Syndrome |
2018-04-20 |
|||
JapicCTI-122041 |
JapicCTI-122041 | P2 |
Completed |
Constipation|Irritable Bowel Syndrome |
2013-12-31 |